Iben Spanggaard
Impact in
- Biotechnology top 10%
- Microbial Inactivation Methods
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Fibroblast Growth Factor Research 6
- Viral Infectious Diseases and Gene Expression in Insects 3
- Oncology 16
- HER2/EGFR in Cancer Research 4
- Cancer Immunotherapy and Biomarkers 3
- Peptidase Inhibition and Analysis 3
- Co-authors
- Birthe Lykke Thomsen (1 shared paper)Anne Tjønneland (1 shared paper)Kim Overvad (1 shared paper)Janne Bigaard (1 shared paper)Kristoffer Staal Rohrberg (20 shared papers)Ulrik Lassen (16 shared papers)Julie Gehl (7 shared papers)Christina W. Yde (9 shared papers)
- Journals
- Annals of Oncology (8 papers)Journal of Clinical Oncology (6 papers)Acta Oncologica (3 papers)Advanced Healthcare Materials (2 papers)Frontiers in Oncology (2 papers)
- Partner nations
- DenmarkUnited StatesFrance
In The Last Decade
Iben Spanggaard
38 papers receiving 603 citations
Peers
Comparison fields: 5 of 66
- Biotechnology 87
- Oncology 213
- Cancer Research 97
- Genetics 31
- Pulmonary and Respiratory Medicine 87
Countries citing papers authored by Iben Spanggaard
This map shows the geographic impact of Iben Spanggaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iben Spanggaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iben Spanggaard more than expected).
Fields of papers citing papers by Iben Spanggaard
This network shows the impact of papers produced by Iben Spanggaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iben Spanggaard. The network helps show where Iben Spanggaard may publish in the future.
Co-authors
The 25 scholars most cited alongside Iben Spanggaard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 46 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 89 | |
| 2 | 2018 | 63 | |
| 3 | 2013 | 63 | |
| 4 | 2024 | 48 | |
| 5 | 2024 | 34 | |
| 6 | 2021 | 26 | |
| 7 | 2021 | 26 | |
| 8 | 2023 | 20 | |
| 9 | 2022 | 18 | |
| 10 | 2022 | 17 | |
| 11 | 2011 | 17 | |
| 12 | 2024 | 17 | |
| 13 | 2021 | 16 | |
| 14 | 2019 | 15 | |
| 15 | 2021 | 15 | |
| 16 | 2022 | 14 | |
| 17 | 2020 | 13 | |
| 18 | 2019 | 13 | |
| 19 | 2020 | 12 | |
| 20 | 2017 | 12 |
About Iben Spanggaard
Iben Spanggaard is a scholar working on Molecular Biology, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Biotechnology, having authored 46 papers that have together received 614 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (8 papers), Fibroblast Growth Factor Research (6 papers), Microbial Inactivation Methods (6 papers), HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Viral Infectious Diseases and Gene Expression in Insects (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Biotechnology (87 citations), Oncology (213 citations), Cancer Research (97 citations), Genetics (31 citations) and Pulmonary and Respiratory Medicine (87 citations). Iben Spanggaard has collaborated with scholars based in Denmark, United States and France. Frequent co-authors include Birthe Lykke Thomsen, Anne Tjønneland, Kim Overvad, Janne Bigaard, Kristoffer Staal Rohrberg, Ulrik Lassen, Julie Gehl, Christina W. Yde, Morten Mau‐Sørensen and Finn Cilius Nielsen. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Acta Oncologica, Advanced Healthcare Materials and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.